CZCamilo Zurita-Salinas

Camilo Zurita-Salinas

*This is an algorithmically generated author record based on publicly available information.

Camilo Zurita-Salinas has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Jeannete Zurita

    Pontificia Universidad Católica del Ecuador, Facultad de Medicina, Quito, Ecuador; Unidad de Investigaciones en Biomedicina, Zurita & Zurita Laboratorios, Quito, Ecuador

    5 shared publications
  • Gabriela Sevillano

    Biomedical Research Unit,Zurita & Zurita Laboratories,Quito,Ecuador; Group of Emerging and Neglected Diseases, Faculty of Health Sciences,Universidad Internacional SEK,Quito,Ecuador, Ecuador

    3 shared publications
  • Ariane Paz Y Miño

    Unidad de Investigaciones en Biomedicina. Zurita & Zurita Laboratorios, Quito, Ecuador; Mass General Brigham Salem Hospital, Salem, MA, USA

    2 shared publications
  • Abraham Aguilar-Campos

    Blood Bank Laboratory, Hospital General de Zona #30, Instituto Mexicano del Seguro Social (IMSS), Mexicali, Mexico

    1 shared publication
  • Ana María Tito-Álvarez

    Nursing School, Faculty of Health Sciences, Universidad de las Américas (UDLA), Quito, Ecuador

    1 shared publication
  • Andrés Andrade-Muñoz

    Facultad de Medicina Pontificia Universidad Católica del Ecuador Quito Ecuador

    1 shared publication

Latest Publications

  • Open Access

    Phylogenetic Analysis of Clinical Non-Tuberculous Mycobacteria Using 16S rRNA, hsp65 and rpoB Gene Markers: Implications for Species Identification and Clinical Management

    by Gabriela Sevillano, Jeannete Zurita, José R. Ramírez-Iglesias, Camilo Zurita-Salinas, Juan-Carlos Navarro

    Due to the differential treatment required by non-tuberculous mycobacteria (NTM) infections, accurate identification in clinical isolates is necessary for correct management, effective treatment, and appropriate control strategies. Traditional methods, including phenotypic tests, are slow, cumbersome, and often not definitive. PCR-based methods, such as restriction fragment length polymorphism analysis, are still very time-consuming and sometimes lead to inaccurate identification because they handle fragments of different sequences but do not agree with their evolutionary origin. Sequencing is the most accurate method for species identification, with the 16S rRNA, hsp65, and rpoB genes being considered as candidates for phylogenetic and diagnostic studies. In this study, we developed a phylogenetic analysis using the 16S rRNA, hsp65, and rpoB gene sequences of Mycobacterium clinical isolates, collected between 2018 and 2022, for taxonomic categorization of Mycobacterium species, and evaluated their use for Mycobacterium species identification of clinical interest. In addition, we analyzed the genotype-phenotype correlation using characteristics such as sample origin, growth rate, and antimicrobial resistance. An alignment matrix was built (MacVector 18.5.8) based on the sequences generated in this study and sequences retrieved from NCBI, and phylogenetic analyses were performed using PAUP 4.0a. The rpoB and hsp65 markers showed phylogenetic information at the level of groups of species and subspecies, while the 16S rRNA gene was shown to be the most conserved gene, yielding a structure at the level of species complexes that can be used as a first level of identification. The clinical isolates showed phylogenetic homology with the M. abscessus, M. avium, M. fortuitum, and M. intracellulare groups. The synapomorphic characters varied between genes analyzed, showing a correlation between genotype and phenotype useful for evolutionary trends, natural classification, and molecular identification methods for clinical and treatment purposes. Keywords: taxonomy; mycobacterial classification; phylogenetics; homology; clinical isolates; molecular identification; genotypic-phenotypic correlation.

  • Top Cited Papers
    Open Access

    The evolutionary history and unique genetic diversity of Indigenous Americans

    by Marcos Araújo Castro e Silva, Kelly Nunes, Maíra R. Ribeiro, Hemanoel Passarelli-Araujo, Renan Barbosa Lemes, Lilian Kimura, Putira Sacuena, Carlos Eduardo G. Amorim, Maria Cátira Bortolini, José Geraldo Mill, et al.

    Indigenous peoples of America represent the last principal expansion of humans across the globe1, yet their genetic history remains one of the least explored2. Although these populations have inhabited the continent for thousands of years3, their evolutionary history remains largely unresolved4,5, owing to the limited availability of genomic data. Here we present data on 128 high-coverage Indigenous American genomes and show they harbour extensive and previously uncharacterized genetic diversity, reflecting at least three dispersals into South America, followed by regional differentiation and long-term continuity. We identified widespread natural selection signals in genes associated with immunity, metabolism, reproduction and development, which were shaped by adaptation to diverse environmental conditions. Notably, several genomic regions exhibit a remarkable allele sharing with Australasian populations, probably originating from an ancient admixture event and partly maintained by selection for more than 10,000 years. We also detected distinct contributions from archaic humans with adaptive introgression affecting key biological functions. The limited overlap between the regions of Australasian affinity and archaic ancestry indicates independent evolutionary origins of these signals. These findings challenge simplified models of continental settlements and show a more dynamic and complex evolutionary history for the Indigenous peoples in America.


  • Open Access

    226. Low incidence of Pseudomonas species in Gram negative blood stream infections in nine hospitals across Ecuador: an unexpected find

    by Jeannete Zurita, Gabriela Sevillano, Maria Belen Solis, Ariane Paz Y Miño, Beatriz Rizkallah Alves, Camilo Zurita-Salinas, Ecuadorian Bacteremia

    Over the last years, several studies on bloodstream infections (BSI) have ranked P. aeruginosa in the top 5 list of Gram-negative causal agents. However, there is very limited data regarding the incidence of Pseudomonas bacteremia in Latin America. The aim of this study was to establish the incidence of bacteremia caused by Pseudomonas species During the period from November 2021 to May 2022 in 9 hospitals in Ecuador, blood culture samples were taken according to the clinical requirements of each patient. The bacteria identification was carried out using automated system (Vitek2 and Phoenix1000) and was confirmed by proteomic (MALDITOF) and molecular sequencing. Antimicrobial susceptibility was performed according to CLSI 2021. This study provided relevant information on BSI caused by Pseudomonas in Ecuador.There are only few population-based studies evaluating bacteremia epidemiology in Latin America. SENTRY in 1997 estimated that P. aeruginosa contributed to 10.6% of gram-negative nosocomial and community-acquired bloodstream infections. Lower incidence levels, as seen in this study (0.043%), could help better understand population trends and help guide treatment. Jeannete Zurita, n/a, Pfizer: Grant/Research Support

  • Open Access

    Vitamin D deficiency and toxicity across 2018 to 2022 in several cities of Ecuador: interrupted time series and a cross-sectional study

    by Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín, Jeannete Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-Muñoz, José Pareja-Maldonado

    Objectives: to identify differences in mean vitamin D concentrations in samples obtained from a private laboratory in the city of Quito, and to explore their relationship with the pre-pandemic and pandemic periods spanning from 2018 to 2022. Design: A combination of an interrupted time series design and a retrospective cross-sectional approach Setting and participants: The study involved 9,285 participants who had their 25-hydroxyvitamin D (25(OH)D) levels tested at a well-known private laboratory in Quito, Ecuador, from 2018 to 2022. Primary and secondary outcome measures: The 25(OH)D levels were analyzed and assessed for correlations with both age and the year in which the measurements were taken. Results: The mean 25-hydroxyvitamin D (25(OH)D) level was 27.53 ng/mL (± 14.11). Approximately 64.58% of participants had insufficient levels, below 20 ng/mL, and 0.62% showed potential harm from excess 25(OH)D, with levels over 100 ng/mL. The analysis indicated a significant monthly increase of 0.133 units in 25(OH)D levels (p=0.006). However, the period after March 2020, compared to before, saw a non-significant decrease of 1.605 units in mean 25(OH)D levels (p=0.477). Conclusions: The study’s findings indicate a significant prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency, underscoring the necessity for preventative measures. Nevertheless, the rise in cases of vitamin D toxicity is concerning, emphasizing the importance of prudent vitamin D supplement prescriptions and public education against self-medication. For efficient resource allocation and targeting those with higher risks, it may be advantageous to concentrate vitamin D testing on specific population groups.


  • Open Access

    Mutations associated with Helicobacter pylori antimicrobial resistance in the Ecuadorian population

    by Jeannete Zurita, Gabriela Sevillano, Ariane Paz Y Miño, Camilo Zurita-Salinas, Vicente Peñaherrera, Manuel Echeverría, Helicobacter pylori Research Group, Hugo Navarrete, María Ángeles Silva Casares, Ivonne Orellana Narvaez, et al.

    Aims We describe the presence of Helicobacter pylori (HP) and estimated the prevalence of primary and secondary resistance using molecular detection in gastric biopsies of Ecuadorian patients. Methods and Results A 66.7% (238/357) of the patients demonstrated the presence of HP using CerTest qPCR. Of these 69.79% (104/149) without previous HP eradication treatment and 64.42% (134/208) with prior HP eradication treatment. The mutation-associated resistance rate for clarithromycin was 33.64% (Primary resistance) and 32.82% (Secondary resistance). While that in levofloxacin the primary and secondary resistance was 37.38% and 42%, respectively. For tetracycline and rifabutin, primary and secondary resistance was 0%. Primary and secondary resistance for metronidazole and amoxicillin could not be evaluated by genotypic methods (PCR and sequencing). Conclusions The analysis of mutations in gyrA, 23S rRNA, and 16S rRNA is useful is useful to detect bacterial resistance as a guide for eradication therapy following failure of the first-line regimen. Significance and Impact of Study This study carried out in an Ecuadorian population indicates that the resistance of HP to first-line antibiotics is high, which may contribute to the high rates of treatment failure, and other treatment alternatives should be considered.


  • Genetic diversity and drug resistance of Mycobacterium tuberculosis in Ecuador

    by J. Zurita, N. Espinel, P. Barba, D. Ortega-Paredes, C. Zurita-Salinas, Y. Rojas, I. Alcocer

    BACKGROUND: The genetic diversity of Mycobacterium tuberculosis in Quito, Ecuador is not well known. OBJECTIVE: To investigate mutations related to drug resistance and bacterial genotypes in M. tuberculosis strains in Ecuador. DESIGN: This was a retrospective study of M. tuberculosis isolates from 104 patients. Isolates were phenotypically resistant to rifampicin (RMP) and/or isoniazid (INH). The genotype was determined using 24-locus mycobacterial interspersed repetitive units-variable-number tandem repeats (MIRU-VNTR). RESULTS: Isolates showed mutations in the rpoB and katG genes, and the inhA promoter. In rpoB, we found 13 genetic alterations at codons 511, 513, 514, 515, 516, 526 and 531. Forty-six (44.2%) RMP-resistant isolates belonged to codon 531. In katG, there were nine genetic alterations at codons 296, 312, 314, 315, 322, 324 and 351. Fifty-three (51%) INH-resistant isolates belonged to codon 315. Five mutations not previously described were identified in katG: Thr324Ser, Thr314Ala, Ala312Pro, Trp351Stop and deleted G at 296 codon. The Latin American Mediterranean (LAM) (33.7%) and Ghana (30.8%) lineages presented most of the main mutations observed. CONCLUSION: This is the first report from Ecuador; it describes five new mutations in katG and indicates that LAM is the most prevalent lineage.


  • Open Access

    Prevalence of common hemoglobin variants in an afro-descendent Ecuadorian population

    by Yamila Domínguez, Camilo Zurita, Diego Calvopiña, Jacqueline Villacís, Marcelo Mora

    Background: Hemoglobinopathies are among the most studied and frequent pathologies. These genetic disorders are considered a very important health care threat in many tropical countries. Ecuador is a tropical Latin-American country with an important presence of afro-descendants (7.2%). Afro-descendants are among the ethnic groups with higher frequency of hemoglobinopathies reported. Ambuqui is a region within the Imbabura province with an important presence of afro-descendants (>50%). The present study analyzed the frequency of the most common hemoglobin variants in an asymptomatic afro-descendent population using capillary electrophoresis. Findings: From 114 individuals, 25 (22%) reported a hemoglobin variant. All individuals that presented hemoglobin variants were heterozygotes (asymptomatic). Hemoglobin S (sickle cell trait) was the most frequent variant found (14%), followed by hemoglobin E (4.4%), Fetal (2.6%) and C (1%). Conclusion: Prevalence of hemoglobin S was consistent with populations from other countries, but it was lower than other Ecuadorian afro-descendent populations. Frequency of hemoglobin C was lower than other afro-descendent populations. This data suggests the possibility of gene flow from Native American individuals to the Ambuqui population there by lowering the frequency of their hemoglobin variants compared with other afro-descendant populations. Evaluating the frequency of hemoglobinopathies in Ecuadorian populations is essential. Despite the high frequency of these disorders, very few health care facilities implement hemoglobinopathies tests as a routine practice.